In this first U.S. series, catheter ablation of VAs with a lattice-tip RFA/PFA catheter appeared effective and generally safe. Caution should be exercised when applying #PFA in proximity to exposed conductors of implantable cardiac devices. https://t.co/6RrCv5TeR9 #JACCCEP
NOW AVAILABLE: The PulseSelect™ PFA system clinical compendium. Discover clinical evidence supporting PFA with the PulseSelect™ PFA system. Download:
https://t.co/Ekgb02VQ6J
See risk info:
https://t.co/6G3fUmdR5h,
https://t.co/ilhSWSqMOL,
https://t.co/1qyd5qQFpt
The evolution of Sphere-9™ ⚡
Dr Miguel Valderrabano discusses lesion consistency, bidirectional block and the clinical development of hybrid RF and PFA technology from pre-clinical models to first-in-human studies.
#Electrophysiology#EPeeps#AFablation
We are excited that the first U.S. sites in the Sphere VT pivotal trial have now been activated. This trial reflects Medtronic's intent to broaden treatment options for patients with ischemic VT using the Sphere-9™ catheter.
Read the announcement: https://t.co/kN1vcY6YoS
La notizia della fine di un programma radiofonico storico ed importante come @caterpillarrai lascia senza parole @MassimoCirri@RaiRadio2
“Direzione Rai Palesemente OSTILE”
Dr. Pasquale Santangeli is presenting a complex ventricular arrhythmia substrate for VT ablation with Affera at #EPLive2026:
🔹 70yo male with ICM (EF 38% improved to 50% on GDMT) & severe COPD
🔹 History of prior mmVT arrest s/p dual-chamber ICD and PCI to the RCA
🔹 Reviewing procedural safety and stratification utilizing the PAINESD risk score.
#EPLiveAustin #EPLive #Cardiology #EPMidst #VTAblation
A remarkable case on the screen at #EPLive2026! Dr. Patrick M. Hranitzky is presenting on AF ablation with transhepatic access. 🗺️💉
Discussing a 46yo man with complex CHD, mechanical valves, and an interrupted IVC. When standard femoral access isn't an option, structural creativity takes over! 🧠🫀
#EPLiveAustin #EPLive #Cardiology #EPMidst
Back on screen at #EPLive2026: Dr. Khaled Awad presents another compelling VT ablation case using the Affera mapping & ablation system. 🗺️⚡️
Discussing a complex 71yo man with ICM, a chronically occluded LAD, LVEF of 25%, and recurrent VT at 150 bpm.
#EPLiveAustin #EPLive #Cardiology #EP
🎬 Case Review at #EPLive2026 | Dr. Amin Al Ahmad reviews Aferra 360 (Medtronic). Circumferential PFA delivery — designed for complete, single-deployment PV antral coverage. Is 360-degree pulsed field isolation the future of first-pass success? 🔁⚡ #Aferra360#Medtronic#PFA #EPeeps
Medtronic received FDA approval to begin a pivotal trial evaluating the Affera™ mapping and ablation system, with updated ablation software, used with the Sphere-9™ catheter for the treatment of monomorphic ventricular tachycardia (VT).
Learn more: https://t.co/DhsLliha12
Truly exciting to see the pivotal trial approved! 🚀
A major milestone for advancing VT care.
Congrats to everyone involved and looking forward to how this study can impact VT patients and @EPeeps. 👏
#Sphere9VT 🫀
#Medtronic, @AfferaEP#Medtronicemployee
PFA for non-PV AF Targets on #HRS2026 1/3
Sphere-9 MI Ablation by @DrSGoyalEP
➡️100pts RF+VOM vs 100pts Sphere9
➡️Sphere-9 showed 97% acute block success, was 10x faster,93% less fluoroscopy compared to RF+VOM
➡️complete elimination of inducible perimitral Flutter
@HRSonline
Redefining VT ablation.
Late-breaking clinical trial data presented at #HRS2026: Six-month results from the Sphere-9™ VT Early Feasibility Study.
Product usage represented may not be approved or cleared in all markets.
Learn more: https://t.co/ZwKyaRYd4e
#Sphere9#Affera
Close-Unipolar™ mapping combines the benefits of bipolar and unipolar electrograms, while avoiding the challenges of each.
Learn more: https://t.co/XyjmCXRrpU
See risk info: https://t.co/XyjmCXRrpU
Products and usage represented may not be approved or cleared in all markets.